Prof. M.H.J. van Oers PhD publications

2020

• de Heer Koen Exhaled breath analysis in the diagnosis of invasive pulmonary aspergillosis 2020. 193p. ISBN 9789463808156. [UvA Dissertations Online] University of Amsterdam. (Supervisors: van Oers Marinus H. J., Sterk Peter J.)
• Saberi Hosnijeh Fatemeh, van der Straten Lina, Kater Arnon P., van Oers Marinus H. J., Posthuma Ward F. M., Chamuleau Martine E. D., Bellido Mar, Doorduijn Jeanette K., van Gelder Michel, Hoogendoorn Mels, de Boer Fransien, te Raa G. Doreen, Kerst J. Martijn, Marijt Erik W. A., Raymakers Reinier A. P., Koene Harry R., Schaafsma Martijn R., Dobber Johan A., Tonino Sanne H., Kersting Sabina S., Langerak Anton W., Levin Mark-David Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study Experimental hematology 2020;89:55-60.e6 [PubMed]

2019

• Leeksma Alexander C., Taylor Justin, Wu Bian, Gardner Jeffrey R., He Jie, Nahas Michelle, Gonen Mithat, Alemayehu Wendimagegn G., te Raa Doreen, Walther Tatjana, Hüllein Jennifer, Dietrich Sascha, Claus Rainer, de Boer Fransien, de Heer Koen, Dubois Julie, Dampmann Maria, Dürig Jan, van Oers Marinus H. J., Geisler Christian H., Eldering Eric, Levine Ross L., Miller Vincent, Mughal Tariq, Lamanna Nicole, Frattini Mark G., Heaney Mark L., Zelenetz Andrew, Zenz Thorsten, Abdel-Wahab Omar, Kater Arnon P. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia Leukemia 2019;33 (2):390-402 [PubMed]
• Kater Arnon P., van Oers Marinus H. J., van Norden Yvette, van der Straten Lina, Driessen Julia, Posthuma Ward F. M., Schipperus Martin, Chamuleau Martine E. D., Nijland Marcel, Doorduijn Jeanette K., van Gelder Michel, Hoogendoorn Mels, de Croon Francien, Wittebol Shulamiet, Kerst J. Martijn, Marijt Erik W. A., Raymakers Reinier A. P., Schaafsma Martijn R., Dobber Johan A., Kersting Sabina, Levin Mark-David Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia Haematologica 2019;104 (1):147-154 [PubMed]
• van Oers Marinus, Smolej Lukas, Petrini Mario, Offner Fritz, Grosicki Sebastian, Levin Mark-David, Davis Jaclyn, Banerjee Hiya, Stefanelli Tommaso, Hoever Petra, Geisler Christian Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study Blood cancer journal 2019;9 (12) [PubMed]
• Preuss Klaus-Dieter, Hollak Carla E. M., Fadle Natalie, van Oers Marinus, Regitz Evi, Pfreundschuh Michael Saposin C is a frequent target of paraproteins in Gaucher disease-associated MGUS/multiple myeloma British journal of haematology 2019;184 (3):384-391 [PubMed]

2018

• Gerritsen M. G., Brinkman P., Escobar N., Bos L. D., de Heer K., Meijer M., Janssen H.-G., de Cock H., Wösten H. A. B., Visser C. E., van Oers M. H. J., Sterk P. J. Profiling of volatile organic compounds produced by clinical Aspergillus isolates using gas chromatography-mass spectrometry Medical mycology 2018;56 (2):253-256 [PubMed]
• van Tuijn Charlotte F. J. Sickle cell disease: Evaluation and management of disease burden 2018. ISBN 9789463610940. [UvA Dissertations Online] University of Amsterdam. (Supervisor: van Oers M. H. J.; Co-supervisor: Biemond B. J.)

2017

• Younes A., Hilden P., Coiffier B., Hagenbeek A., Salles G., Wilson W., Seymour J. F., Kelly K., Gribben J., Pfreunschuh M., Morschhauser F., Schoder H., Zelenetz A. D., Rademaker J., Advani R., Valente N., Fortpied C., Witzig T. E., Sehn L. H., Engert A., Fisher R. I., Zinzani P.-L., Federico M., Hutchings M., Bollard C., Trneny M., Elsayed Y. A., Tobinai K., Abramson J. S., Fowler N., Goy A., Smith M., Ansell S., Kuruvilla J., Dreyling M., Thieblemont C., Little R. F., Aurer I., van Oers M. H. J., Takeshita K., Gopal A., Rule S., de Vos S., Kloos I., Kaminski M. S., Meignan M., Schwartz L. H., Leonard J. P., Schuster S. J., Seshan V. E. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) Annals of oncology 2017;28 (7):1436-1447 [PubMed]
• Vidal Liat, Gafter-Gvili Anat, Salles Gilles, Bousseta Sami, Oberman Bernice, Rubin Carmit, van Oers Marinus H. J., Fortpied Catherine, Ghielmini Michele, Pettengell Ruth, Witzens-Harig Mathias, Dreger Peter, Vitolo Umberto, Gomes da Silva Maria, Evangelista Andrea, Li Hailun, Freedman Laurence, Habermann Thomas M., Shpilberg Ofer Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis European journal of cancer (Oxford, England 2017;76:216-225 [PubMed]
• Schimmel Marein Sickle cell disease: Pathogenesis and biomarkers 2017. 205p. ISBN 9789492683441. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Brandjes D. P. M. , van Oers M. H. J.; Co-supervisors: Biemond B. J. , Zeerleder S. S.)
• Vojdeman Fie J., Herman Sarah E. M., Kirkby Nikolai, Wiestner Adrian, van T' Veer Mars B., Tjønnfjord Geir E., Itälä-Remes Maija A., Kimby Eva, Farooqui Mohammed Z., Polliack Aaron, Wu Ka Lung, Doorduijn Jeanette K., Alemayehu Wendimagegn G., Wittebol Shulamiet, Kozak Tomas, Walewski Jan, Abrahamse-Testroote Martine C. J., van Oers Marinus H. J., Geisler Christian H., Niemann Carsten U. Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia Leukemia & lymphoma 2017;58 (10):2356-2362 [PubMed]
• Vojdeman Fie Juhl, van't Veer Mars B., Tjønnfjord Geir E., Itälä-Remes Maija, Kimby Eva, Polliack Aaron, Wu Ka L., Doorduijn Jeanette K., Alemayehu Wendimagegn G., Wittebol Shulamiet, Kozak Tomas, Walewski Jan, Abrahamse-Testroote Martine C. J., van Oers Marinus H. J., Geisler Christian Hartmann The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia Leukemia & lymphoma 2017;58 (3):594-600 [PubMed]
• Sins Joep W. R. Therapeutic targets in sickle cell disease 2017. 283p. ISBN 9789492683960. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Fijnvandraat C. J., van Oers M. H. J.; Co-supervisors: Biemond B. J., Kuijpers T. W.)

2016

• van Oers Marinus H. J. Analysis of prognosis in CLL: collaboration makes the difference lancet oncology 2016;17 (6):691-692 [PubMed]
• de Heer K., Kok M. G. M., Fens N., Weersink E. J. M., Zwinderman A. H., van der Schee M. P. C., Visser C. E., van Oers M. H. J., Sterk P. J. Correction for de Heer et al., Detection of Airway Colonization by Aspergillus fumigatus by Use of Electronic Nose Technology in Patients with Cystic Fibrosis Journal of clinical microbiology 2016;54 (7):1926 [PubMed]
• de Heer K., Kok M. G. M., Fens N., Weersink E. J. M., Zwinderman A. H., van der Schee M. P. C., Visser C. E., van Oers M. H. J., Sterk P. J. Detection of Airway Colonization by Aspergillus fumigatus by Use of Electronic Nose Technology in Patients with Cystic Fibrosis Journal of clinical microbiology 2016;54 (3):569-575 [PubMed]
• Kersting S., Levin M.-D., Chamuleau M., Daenen S. M. G. J., Dompeling E. C., Doorduijn J. K., van Gelder M., Hoogendoorn M., Kerst J. M., Nijland M., Nijziel M. R., Posthuma E. F. M., Raymakers R. A. P., Schaafsma M. R., Silbermann M. H., van der Straaten H. M., Veelken J. H., Vos J. M. I., Wittebol S., van Oers M. H. J., Kater A. P. Dutch guidelines for the diagnosis and treatment of chronic lymphocytic leukaemia Netherlands journal of medicine 2016;74 (2):68-74 [PubMed]
• van Gelder M., van Oers M. H., Alemayehu W. G., Abrahamse-Testroote M. C. J., Cornelissen J. J., Chamuleau M. E., Zachée P., Hoogendoorn M., Nijland M., Petersen E. J., Beeker A., Timmers G.-J., Verdonck L., Westerman M., de Weerdt O., Kater A. P. Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study Bone marrow transplantation 2016;51 (6):799-806 [PubMed]
• de Heer K., Vonk S. I., Kok M., Kolader M., Zwinderman A. H., van Oers M. H. J., Sterk P. J., Visser C. E. eNose technology can detect and classify human pathogenic molds in vitro: a proof-of-concept study of Aspergillus fumigatus and Rhizopus oryzae Journal of breath research 2016;10 (3):036008 [PubMed]
• Munneke J. Marius Innate lymphoid cells in inflammation and repair 2016. 184p. ISBN 9789402801880. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Spits H., van Oers M. H. J.; Co-supervisor: Hazenberg M. D.)
• Fleury I., Chevret S., Pfreundschuh M., Salles G., Coiffier B., van Oers M. H. J., Gisselbrecht C., Zucca E., Herold M., Ghielmini M., Thieblemont C. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis Annals of oncology 2016;27 (3):390-397 [PubMed]
• Thijssen R., ter Burg J., van Bochove G. G. W., de Rooij M. F. M., Kuil A., Jansen M. H., Kuijpers T. W., Baars J. W., Virone-Oddos A., Spaargaren M., Egile C., van Oers M. H. J., Eldering E., Kersten M. J., Kater A. P. The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells Leukemia 2016;30 (2):337-345 [PubMed]
• Thijssen R., ter Burg J., van Bochove G. G. W., de Rooij M. F. M., Kuil A., Jansen M. H., Kuijpers T. W., Baars J. W., Virone-Oddos A., Spaargaren M., Egile C., van Oers M. H. J., Eldering E., Kersten M. J., Kater A. P. The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 ( voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells (Vol 30, pg 337, 2016) Leukemia 2016;30 (9):1963 [PubMed]

2015

• te Raa G. D., Moerland P. D., Leeksma A. C., Derks I. A., Yigittop H., Laddach N., Loden-van Straaten M., Navrkalova V., Trbusek M., Luijks D. M., Zenz T., Skowronska A., Hoogendoorn M., Stankovic T., van Oers M. H., Eldering E., Kater A. P. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification Cell death & disease 2015;6:e1852 [PubMed]
• Mank Arno P. M., Schoonenberg Charlot, Bleeker Kim, Heijmenberg Susanne, Heer Koen de, van Oers Marinus H. J., Kersten Marie José Early discharge after high dose chemotherapy is safe and feasible: a prospective evaluation of 6 years of home care Leukemia & lymphoma 2015;56 (7):2098-2104 [PubMed]
• Hazenberg Bouke P. C., Croockewit Alexandra, van der Holt Bronno, Zweegman Sonja, Bos Gerard M. J., Delforge Michel, Raymakers Reinier A. P., Sonneveld Pieter, Vellenga Edo, Wijermans Pierre W., von dem Borne Peter A., van Oers Marinus H., de Weerdt Okke, Spoelstra Fokje M., Lokhorst Henk M. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology Haematologica 2015;100 (5):677-682 [PubMed]
• Lauw Mandy Nicole Hypercoagulability in hematological malignancies 2015. 293p. ISBN 9789461697097. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Middeldorp S., van Oers M. H. J.; Co-supervisor: Biemond B. J.)
• Tonino Sanne H., Mulkens Chantal E., van Laar Jacoline, Derks Ingrid A. M., Suo Guangli, Croon-de Boer Fransien, van Oers Marinus H. J., Eldering Eric, Wang Jean Y., Kater Arnon P. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia Leukemia & lymphoma 2015;56 (8):2439-2447 [PubMed]
• te Raa Gera Doreen Molecular characteristics and prognosis in CLL 2015. 240p. ISBN 9789461825315. [UvA Dissertations Online] University of Amsterdam. (Supervisors: van Oers M. H. J., Eldering E. F.; Co-supervisor: Kater A. P.)
• van Oers Marinus H. J., Kuliczkowski Kazimierz, Smolej Lukáš, Petrini Mario, Offner Fritz, Grosicki Sebastian, Levin Mark-David, Gupta Ira, Phillips Jennifer, Williams Vanessa, Manson Stephanie, Lisby Steen, Geisler Christian Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study lancet oncology 2015;16 (13):1370-1379 [PubMed]
• Holtzer-Goor K. M., Schaafsma M. R., Joosten P., Posthuma E. F. M., Wittebol S., Huijgens P. C., Mattijssen E. J. M., Vreugdenhil G., Visser H., Peters W. G., Erjavec Z., Wijermans P. W., Daenen S. M. G. J., van der Hem K. G., van Oers M. H. J., Uyl-de Groot C. A. Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study Quality of life research 2015;24 (12):2895-2906 [PubMed]
• Lokhorst Henk M., van der Holt Bronno, Cornelissen Jan J., Kersten Marie José, van Oers Marinus, Raymakers Reinier, Minnema Monique C., Zweegman Sonja, Bos Gerard, Schaap Nicolaas, Wittebol Shulamiet, de Weerdt Okke, Ammerlaan Rianne, Sonneveld Pieter Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival Haematologica 2015;100 (12):e508-e510 [PubMed]
• Thijssen Rachel, Slinger Erik, Weller Katinka, Geest Christian R., Beaumont Tim, van Oers Marinus H. J., Kater Arnon P., Eldering Eric Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors Haematologica 2015;100 (8):e302-e306 [PubMed]
• te Raa G. D., Derks I. A. M., Navrkalova V., Skowronska A., Moerland P. D., van Laar J., Oldreive C., Monsuur H., Trbusek M., Malcikova J., Lodén M., Geisler C. H., Hüllein J., Jethwa A., Zenz T., Pospisilova S., Stankovic T., van Oers M. H. J., Kater A. P., Eldering E. The impact of SF3B1 mutations in CLL on the DNA-damage response Leukemia 2015;29 (5):1133-1142 [PubMed]

2014

• Munneke J. Marius, Björklund Andreas T., Mjösberg Jenny M., Garming-Legert Karin, Bernink Jochem H., Blom Bianca, Huisman Cynthia, van Oers Marinus H. J., Spits Hergen, Malmberg Karl-Johan, Hazenberg Mette D. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease Blood 2014;124 (5):812-821 [PubMed]
• te Raa G. Doreen, Malčiková Jitka, Mraz Marek, Trbusek Martin, Le Garff-Tavernier Magali, Merle-Béral Hélène, Greil Rudolf, Merkel Olaf, Pospíšilová Sarka, Lin Ke, Pettitt Andrew R., Stankovic Tatjana, van Oers Marinus H., Eldering Eric, Stilgenbauer Stephan, Zenz Thorsten, Kater Arnon P. Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach British journal of haematology 2014;167 (4):565-569 [PubMed]
• te Raa G. Doreen, Pascutti Maria Fernanda, García-Vallejo Juan J., Reinen Emilie, Remmerswaal Ester B. M., ten Berge Ineke J. M., van Lier René A. W., Eldering Eric, van Oers Marinus H. J., Tonino Sanne H., Kater Arnon P. CMV-specific CD8(+) T-cell function is not impaired in chronic lymphocytic leukemia Blood 2014;123 (5):717-724 [PubMed]
• Kater Arnon P., Spiering Marjolein, Liu Roberto D., Doreen te Raa G., Slinger E., Tonino Sanne H., Beckers Marielle M., Daenen Simon, Doorduijn Jeanette K., Lankheet Nienke A. G., Luijks Dieuwertje M., Eldering Eric, van Oers Marinus H. J. Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study Leukemia research 2014;38 (1):34-41 [PubMed]
• Geisler Christian H., van T' Veer Mars B., Jurlander Jesper, Walewski Jan, Tjønnfjord Geir, Itälä Remes Maija, Kimby Eva, Kozak Tomas, Polliack Aaron, Wu Ka Lung, Wittebol Shulamiet, Abrahamse-Testroote Martine C. J., Doorduijn Jeanette, Ghidey Alemayehu Wendimagegn, van Oers Marinus H. J. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL Blood 2014;123 (21):3255-3262 [PubMed]
• Holtzer-Goor K. M., Bouwmans-Frijters C. A. M., Schaafsma M. R., de Weerdt O., Joosten P., Posthuma E. F. M., Wittebol S., Huijgens P. C., Mattijssen E. J. M., Vreugdenhil G., Visser H., Peters W. G., Erjavec Z., Wijermans P. W., Daenen S. M. G. J., van der Hem K. G., van Oers M. H. J., Groot C. A. Uyl-de Real-world costs of chronic lymphocytic leukaemia in the Netherlands Leukemia research 2014;38 (1):84-90 [PubMed]

2013

• Hovius Joppe W. R., de Wever Bob, Sohne Maaike, Brouwer Matthijs C., Coumou Jeroen, Wagemakers Alex, Oei Anneke, Knol Henrike, Narasimhan Sukanya, Hodiamont Caspar J., Jahfari Setareh, Pals Steven T., Horlings Hugo M., Fikrig Erol, Sprong Hein, van Oers Marinus H. J. A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe Lancet 2013;382 (9892):658 [PubMed]
• Wouters Diana, Stephan Femke, Strengers Paul, de Haas Masja, Brouwer Conny, Hagenbeek Anton, van Oers Marinus H. J., Zeerleder Sacha C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia Blood 2013;121 (7):1242-1244 [PubMed]
• Lascano Valeria, Guadagnoli Marco, Schot Jan G., Luijks Dieuwertje M., Guikema Jeroen E. J., Cameron Katherine, Hahne Michael, Pals Steven, Slinger Erik, Kipps Thomas J., van Oers Marinus H. J., Eldering Eric, Medema Jan Paul, Kater Arnon P. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model Blood 2013;122 (24):3960-3963 [PubMed]
• Maas C., Tromp J. M., van Laar J., Thijssen R., Elias J. A., Malara A., Krippner-Heidenreich A., Silke J., van Oers M. H. J., Eldering E. CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex Cell death & disease 2013;4:e782 [PubMed]
• de Heer Koen, van der Schee Marc P., Zwinderman Koos, van den Berk Inge A. H., Visser Caroline Elisabeth, van Oers Rien, Sterk Peter J. Electronic nose technology for detection of invasive pulmonary aspergillosis in prolonged chemotherapy-induced neutropenia: a proof-of-principle study Journal of clinical microbiology 2013;51 (5):1490-1495 [PubMed]
• Mank Arno P. M. High dose treatment for haematologic malignancies. From rituals to evidence based practice 2013. 215p. ISBN 9789461900296. [UvA Dissertations Online] University of Amsterdam. (Supervisor: van Oers M. H. J.; Co-supervisor: Kersten M. J.)
• Pascutti Maria Fernanda, Jak Margot, Tromp Jacqueline M., Derks Ingrid A. M., Remmerswaal Ester B. M., Thijssen Rachel, van Attekum Martijn H. A., van Bochove Gregor G., Luijks Dieuwertje M., Pals Steven T., van Lier René A. W., Kater Arnon P., van Oers Marinus H. J., Eldering Eric IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells Blood 2013;122 (17):3010-3019 [PubMed]
• te Raa G. Doreen, Malcikova Jitka, Pospisilova Sarka, Trbusek Martin, Mraz Mark, Garff-Tavernier Maria Le, Merle-Béral Hélène, Lin Ke, Pettitt Andrew R., Merkel Olaf, Stankovic Tatjana, van Oers Marinus H., Eldering Eric, Stilgenbauer Stephan, Zenz Thorsten, Kater Arnon P. Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia Leukemia & lymphoma 2013;54 (8):1849-1853 [PubMed]
• Vojdeman Fie Juhl, Jurlander Jesper, Veer Mars Van't, Itälä-Remes Maija, Kimby Eva, Tjønnfjord Geir Erland, Walewski Jan, Kozák Tomas, Polliack Aaron, Montagna Michela, Regazzi Mario, Kirkby Nikolai, Oers Marinus van, Geisler Christian Hartmann Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis Leukemia & lymphoma 2013;54 (4):790-793 [PubMed]
• Jethwa Alexander, Hüllein Jennifer, Stolz Tatjana, Blume Carolin, Sellner Leopold, Jauch Anna, Sill Martin, Kater Arnon P., te Raa G. Doreen, Geisler Christian, van Oers Marinus, Dietrich Sascha, Dreger Peter, Ho Anthony D., Paruzynski Anna, Schmidt Manfred, von Kalle Christof, Glimm Hanno, Zenz Thorsten Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia British journal of haematology 2013;163 (4):496-500 [PubMed]
• de Weerdt Iris, Eldering Eric, van Oers Marinus H., Kater Arnon P. The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia Leukemia research 2013;37 (7):838-847 [PubMed]

2012

• Zeerleder Sacha, van Oers Marinus Aleukemic variant of mast cell leukemia Blood 2012;119 (9):1961 [PubMed]
• van Oers Marinus H. J. CD20 antibodies: type II to tango? Blood 2012;119 (22):5061-5063 [PubMed]
• te Raa G. Doreen, Tonino Sanne H., Remmerswaal Ester B. M., van Houte Arend Jan, Koene Harry R., van Oers Marinus H., Kater Arnon P. Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis Leukemia & lymphoma 2012;53 (11):2321-2325 [PubMed]
• Lokhorst Henk M., van der Holt Bronno, Cornelissen Jan J., Kersten Marie-José, van Oers Marinus, Raymakers Reinier, Minnema Monique C., Zweegman Sonja, Janssen Jeroen J., Zijlmans Mark, Bos Gerard, Schaap Nicolaas, Wittebol Shulamiet, de Weerdt Okke, Ammerlaan Rianne, Sonneveld Pieter Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study Blood 2012;119 (26):6219-6225 [PubMed]
• Halkes C. J., Brand A., Backes E., van Oers M. H., Veelken J. H., Falkenburg J. H. Eerstelijnsbehandeling met immuunsuppressieve therapie bij ernstige aplastische anemie: polyklonale antistoffen zijn niet zonder meer inwisselbaar Nederlands tijdschrift voor hematologie 2012;9:263
• Pospisilova S., Gonzalez D., Malcikova J., Trbusek M., Rossi D., Kater A. P., Cymbalista F., Eichhorst B., Hallek M., Döhner H., Hillmen P., van Oers M., Gribben J., Ghia P., Montserrat E., Stilgenbauer S., Zenz T. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia Leukemia 2012;26 (7):1458-1461 [PubMed]
• Tonino Sanne H., van de Berg Pablo J., Yong Si La, ten Berge Ineke J., Kersten Marie José, van Lier René A. W., van Oers Marinus H., Kater Arnon P. Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia Leukemia & lymphoma 2012;53 (9):1785-1794 [PubMed]
• Kater A. P., Chamuleau M. E., Posthuma W., Schipperus M. R., Spiering M., van Oers M. H. HOVON 109: de effectiviteit en veiligheid van eerstelijnsbehandeling van chronische lymfatische leukemie met chloorambucil, rituximab en lenalidomide bij oudere patienten en patienten met comorbiditeit; een fase I/II-studie Nederlands tijdschrift voor hematologie 2012;9:197
• Jak Margot Microenvironment and anti-CD20 based therapies in CLL 2012. 169p. [UvA Dissertations Online] University of Amsterdam. (Supervisors: van Oers M. H. J., van Lier R. A. W.; Co-supervisor: Eldering E.)
• te Raa G. D., van Oers M. H., Kater A. P. Monoclonal B-cell lymphocytosis: Recommendations from the Dutch Working Group on CLL for daily practice Netherlands journal of medicine 2012;70 (5):236-241 [PubMed]
• te Raa G. D., van Oers M. H., Kater A. P. Monoklonale B-cellymfocytose: incidentie, risicostratificatie en aanbevelingen voor de dagelijkse praktijk Nederlands tijdschrift voor hematologie 2012;9:138
• Bauduer M., Gribben J., Herrmann R., Thiel E., Rai K., Larson R., Ferrara F., Barnard J., Pearce H., Taylor C., Brillant C., Steurer M., Weingart O., Flinn I. W., Funkhouser A., Tallman M., Sun Z., Jaksic B., Suciu S., Chevret S., Dighiero G., Leporrier M., Frankel S. R., Sirard C., Hillmen P., Trehu B., Felder M., Busch R., Eichhorst B., Hallek M., Stilgenbauer S., Pangalis G., Bezares R., van Oers M. H. J., van Putten W., Gobbi M., Spriano M., Mabed M., Catovsky D., Richards S., Wade R., Abdelhamid T., Dearden C., Knauf W., Blonski J., Jamroziak K., Robak T., Mauro F., Hiddeman W., Johnson S. A. Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials Haematologica 2012;97 (3):428-436 [PubMed]
• Tromp Jacqueline M. The microenvironment and treatment resistance in chronic lymphocytic leukemia 2012. 183p. ISBN 9789090269375. [UvA Dissertations Online] University of Amsterdam. (Supervisors: van Oers M. H. J., Eldering E. F.)
• Tromp Jacqueline M., Geest Christian R., Breij Esther C. W., Elias Judith A., van Laar Jacoline, Luijks Dieuwertje M., Kater Arnon P., Beaumont Tim, van Oers Marinus H. J., Eldering Eric Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia Clinical cancer research 2012;18 (2):487-498 [PubMed]
• Kwakernaak A. J., Hazenberg M. D., Roelofs J. J., van Noesel C. J., van Oers M. H., van Tellingen A. T-lymfoblastair lymfoom zich presenterend als primair renaal lymfoom met acute nierinsufficiëntie Nederlands tijdschrift voor hematologie 2012;9:34

2011

• Jak Margot, van Bochove Gregor G. W., Reits Eric A., Kallemeijn Wouter W., Tromp Jacqueline M., Umana Pablo, Klein Christian, van Lier Rene A. W., van Oers Marinus H. J., Eldering Eric CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101 Blood 2011;118 (19):5178-5188 [PubMed]
• Jak M., van Bochove G. G. W., van Lier R. A. W., Eldering E., van Oers M. H. J. CD40 stimulation sensitizes CLL cells to rituximab-induced cell death Leukemia 2011;25 (6):968-978 [PubMed]
• Tonino Sanne H., Rijssenbeek Astrid L., Oud Monique E., Pals Steven T., van Oers Marinus H., Kater Arnon P. Intracerebral Infiltration As the Unique Cause of the Clinical Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Journal of clinical oncology 2011;29 (34):E837-E839 [PubMed]
• Hommes Daniel W., Duijvestein Marjolijn, Zelinkova Zuzana, Stokkers Pieter C. F., Ley Maartje Holsbergen-de, Stoker Jaap, Voermans Carlijn, van Oers Marinus H. J., Kersten Marie José Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease Journal of Crohn s & colitis 2011;5 (6):543-549 [PubMed]
• van Oers Marinus H. J., Jansen Joop H., van der Reijden Bert A. Molecular Remission in Follicular Lymphoma: Is the Era of Residual Disease Monitoring Over? Reply Journal of clinical oncology 2011;29 (11):E319
• Bilgin Yavuz M., van de Watering Leo M. G., Versteegh Michel I. M., van Oers Marinus H. J., Vamvakas Eleftherios C., Brand Anneke Postoperative complications associated with transfusion of platelets and plasma in cardiac surgery Transfusion 2011;51 (12):2603-2610 [PubMed]
• Kwakernaak Arjan J., Hazenberg Mette D., Roelofs Joris J. T. H., van Noesel Carel J. M., van Oers Marinus H. J., van Tellingen Anne Precursor T-lymphoblastic lymphoma presenting as primary renal lymphoma with acute renal failure NDT Plus 2011;4 (5):289-291 [PubMed]
• Kater A. P., Wittebol S., Chamuleau M. E., van Gelder M., van Oers M. H. Richtlijnen diagnostiek en behandeling chronische lymfatische leukemie 2011 Nederlands tijdschrift voor hematologie 2011;8:190-201
• Tonino S. H., van Laar J., van Oers M. H., Wang J. Y., Eldering E., Kater A. P. ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia Oncogene 2011;30 (6):701-713 [PubMed]
• Tonino Sanne H. Targets for the treatment of drug resistant chronic lymphocytic leukemia 2011. 175p. ISBN 9789090264820. [UvA Dissertations Online] University of Amsterdam. (Supervisor: van Oers M. H. J.; Co-supervisors: Kater A. P., Eldering E.)
• van Oers Marinus H. J., Kersten Marie José Treatment strategies in advanced stage follicular lymphoma Best practice & research. Clinical haematology 2011;24 (2):187-201 [PubMed]
• Nur Erfan Vasculopathy in sickle cell disease 2011. 211p. ISBN 9789090260877. [UvA Dissertations Online] University of Amsterdam. (Supervisor: van Oers M. H. J.; Co-supervisors: Biemond B. J., Brandjes D. P. M.)

2010

• van Rijssel Reinier H., Wegman Jurgen, Oud Monique E., Pals Steven T., van Oers Marinus H. J. A case of ATRA-induced isolated myocarditis in the absence of circulating malignant cells: Demonstration of the t(15;17) translocation in the inflammatory infiltrate by in situ hybridisation Leukemia research 2010;34 (7):E142-E144 [PubMed]
• Kneppers Evelien, Lokhorst Henk M., Eeltink Corien M., Huls Gerwin, Kersten Marie José, Koedam Jan, Minnema Monique C., van Oers Marinus H. J., Raymakers Reinier A. P., Schaafsma Martijn R., Vellenga Edo, Wijermans Pierre W., Wittebol Shulamiet, Sonneveld Pieter, Zweegman Sonja Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program Clinical lymphoma, myeloma & leukemia 2010;10 (2):138-143 [PubMed]
• Lokhorst Henk M., van der Holt Bronno, Zweegman Sonja, Vellenga Edo, Croockewit Sandra, van Oers Marinus H., von dem Borne Peter, Wijermans Pierre, Schaafsma Ron, de Weerdt Okke, Wittebol Shulamiet, Delforge Michel, Berenschot Henriëtte, Bos Gerard M., Jie Kon-Siong G., Sinnige Harm, van Marwijk-Kooy Marinus, Joosten Peter, Minnema Monique C., van Ammerlaan Rianne, Sonneveld Pieter A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma Blood 2010;115 (6):1113-1120 [PubMed]
• van Oers Marinus H. J., Tönnissen Evelyn, van Glabbeke Martine, Giurgea Livia, Jansen Joop H., Klasa Richard, Marcus Robert E., Wolf Max, Kimby Eva, Vranovsky Andrej, Holte Harald, Hagenbeek Anton, van der Reijden Bert A. BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study Journal of clinical oncology 2010;28 (13):2246-2252 [PubMed]
• Tromp J. M., Tonino S. H., Elias J. A., Jaspers A., Luijks D. M., Kater A. P., van Lier R. A. W., van Oers M. H. J., Eldering E. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering Oncogene 2010;29 (36):5071-5082 [PubMed]
• Bilgin Yavuz M., van de Watering Leo M. G., Versteegh Michel I. M., van Oers Marinus H. J., Brand Anneke Effects of allogeneic leukocytes in blood transfusions during cardiac surgery on inflammatory mediators and postoperative complications Critical care medicine 2010;38 (2):546-552 [PubMed]
• Oers Marinus H. J. van Hematologie (hoofdstuk 8)in: C. D. A. Stehouwer, R. P. Koopmans, J. Meer, editors. Interne geneeskunde; 14e druk. Houten: Bohn Stafleu Van Loghum; 2010. p. 245-281, ISBN 9789031373604
• Oers Marinus H. J. van HOVON 101: een fase III, open label, gerandomiseerde multicentrische studie naar ofatumumab-onderhoudsbehandeling bij patienten met een recidief chronische lymfatische leukemie die in partiële of complete remissie zijn na re-inductiebehandeling Nederlands tijdschrift voor hematologie 2010;7 (7):294-296
• Coiffier Bertrand, Losic Nedjad, Rønn Birgitte Biilmann, Lepretre Stéphane, Pedersen Lars Møller, Gadeberg Ole, Frederiksen Henrik, van Oers Marinus H. J., Wooldridge James, Kloczko Janusz, Holowiecki Jerzy, Hellmann Andrzej, Walewski Jan, Robak Tadeusz, Petersen Jørgen Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study British journal of haematology 2010;150 (1):58-71 [PubMed]
• Tonino S. H., van Gelder M., Eldering E., van Oers M. H., Kater A. P. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia Leukemia 2010;24 (3):652-654 [PubMed]
• van Oers Marinus H. J., Tönnissen Evelyn, van Glabbeke Martine, Giurgea Livia, Jansen Joop H., Klasa Richard, Marcus Robert E., Wolf Max, Kimby Eva, Vranovsky Andrej, Holte Harald, Hagenbeek Anton, van der Reijden Bert A. Reply to U. Duhrsen et al Journal of clinical oncology 2010;28 (30):e614 [PubMed]
• van Oers Marinus H. J., van Glabbeke Martine, Giurgea Livia, Klasa Richard, Marcus Robert E., Wolf Max, Kimby Eva, van 't Veer Mars, Vranovsky Andrej, Holte Harald, Hagenbeek Anton Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study Journal of clinical oncology 2010;28 (17):2853-2858 [PubMed]
• Vlaar Alexander P., Wortel Kim, Binnekade Jan M., van Oers Marinus H. J., Beckers Erik, Gajic Ognjen, Schultz Marcus J., Juffermans Nicole P. The practice of reporting transfusion-related acute lung injury: a national survey among clinical and preclinical disciplines Transfusion 2010;50 (2):443-451 [PubMed]

2009

• Gunn Shelly R., Bolla Aswani R., Barron Lynn L., Gorre Mercedes E., Mohammed Mansoor S., Bahler David W., Mellink Clemens H. M., van Oers Marinus H. J., Keating Michael J., Ferrajoli Alessandra, Coombes Kevin R., Abruzzo Lynne V., Robetorye Ryan S. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene Leukemia research 2009;33 (9):1276-1281 [PubMed]
• Mous R., Jaspers A., Luijks D. M. P., Mellink C. H. M., van Oers M. H. J., Kater A. P., Eldering E. Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction Leukemia 2009;23 (7):1352-1355 [PubMed]
• Kater A. P., van Oers M. H. J. De tyrosinekinaseremmer dasatinib voor behandeling van chemotherapie-refractaire chronische lymfatische leukemie: de D'ACCORD-studie Nederlands tijdschrift voor hematologie 2009;6 (8):317-320
• Jak Margot, Mous Rogier, Remmerswaal Ester B. M., Spijker René, Jaspers Annelieke, Yagüe Adriana, Eldering Eric, van Lier René A. W., van Oers Marinus H. J. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia Leukemia & lymphoma 2009;50 (5):788-801 [PubMed]
• van 't Veer Mars B., de Jong Daphne, Mackenzie Marius, Kluin-Nelemans Hanneke C., van Oers Marinus H. J., Zijlstra Jose, Hagenbeek Anton, van Putten Wim L. J. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients British journal of haematology 2009;144 (4):524-530 [PubMed]
• Osterborg A., Foà R., Bezares R. F., Dearden C., Dyer M. J. S., Geisler C., Lin T. S., Montillo M., van Oers M. H. J., Wendtner C.-M., Rai K. R. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia Leukemia 2009;23 (11):1980-1988 [PubMed]
• Zenz Thorsten, Mohr Julia, Eldering Eric, Kater Arnon P., Bühler Andreas, Kienle Dirk, Winkler Dirk, Dürig Jan, van Oers Marinus H. J., Mertens Daniel, Döhner Hartmut, Stilgenbauer Stephan miR-34a as part of the resistance network in chronic lymphocytic leukemia Blood 2009;113 (16):3801-3808 [PubMed]
• van Oers M. H. J. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma:moving targets Netherlands journal of medicine 2009;67 (8):309-310 [PubMed]
• Cornelissen Jan J., van der Holt Bronno, Verhoef Gregor E. G., van't Veer Mars B., van Oers Marinus H. J., Schouten Harry C., Ossenkoppele Gert, Sonneveld Pieter, Maertens Johan, van Marwijk Kooy Marinus, Schaafsma Martijn R., Wijermans Pierre W., Biesma Douwe H., Wittebol Shulamit, Voogt Paul J., Baars Joke W., Zachée Pierre, Verdonck Leo F., Löwenberg Bob, Dekker Adriaan W. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison Blood 2009;113 (6):1375-1382 [PubMed]
• Kager Liesbeth M., Kersten Marie-Jose, Kloppenborg Raoul Peter, van Oers Rien, van den Born Bert-Jan Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma BMJ case reports 2009;2009:bcr06.2009.1926 [PubMed]

2008

• Mous Rogier, Savage Philip, Eldering Eric, Teeling Peter, van Oers Marinus Hj, van Lier René Aw Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands Leukemia & lymphoma 2008;49 (8):1592-1602 [PubMed]
• Hallaert Delfine Y. H., Jaspers Annelieke, van Noesel Carel J., van Oers Marinus H. J., Kater Arnon P., Eldering Eric c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches Blood 2008;112 (13):5141-5149 [PubMed]
• van Oers M. H. J. Chronisch Lymfatische Leukemie (hoofdstuk 25)in: Bob Löwenberg, Gert J. Ossenkoppele, editors. Handboek Hematologie. Utrecht: De Tijdstroom; 2008. p. 337-351, ISBN 9789058981325
• Kater A. P., van Oers M. H. J. De plaats van alemtuzumab bij de behandeling van chronische lymfatische leukemie Nederlands tijdschrift voor hematologie 2008;5 (6):236-244
• Hallaert Delfine Y. H. 'From the cradle to the grave' : novel therapeutic approaches to attack the microenvironment in chronic lymphocytic leukemia 2008. 171p. ISBN 9789090235479. [UvA Dissertations Online] University of Amsterdam. (Supervisor: van Oers M. H.; Co-supervisor: Eldering E.)
• de Fost Maaike Gaucher disease type 1; associated morbidities and long term efficcacy of enzyme replacement therapy 2008. 196p. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Aerts Johannes M. F. G., van Oers Marinus H. J.; Co-supervisor: Hollak C. E. M.)
• de Fost M., Out T. A., de Wilde F. A., Tjin E. P. M., Pals S. T., van Oers M. H. J., Boot R. G., Aerts J. F. M. G., Maas M., vom Dahl S., Hollak C. E. M. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature Annals of hematology 2008;87 (6):439-449 [PubMed]
• van Gent Rogier, Kater Arnon P., Otto Sigrid A., Jaspers A., Borghans José A. M., Vrisekoop Nienke, Ackermans Mariëtte A. T., Ruiter An F. C., Wittebol Shulamiet, Eldering Eric, van Oers Marinus H. J., Tesselaar Kiki, Kersten Marie José, Miedema Frank In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow Cancer research 2008;68 (24):10137-10144 [PubMed]
• Tonino Sanne H., Spijker Rene, Luijks Dieuwertje M. P., van Oers Marinus H. J., Kater Arnon P. No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia Blood 2008;112 (3):840-843 [PubMed]
• Morschhauser Franck, Radford John, van Hoof Achiel, Vitolo Umberto, Soubeyran Pierre, Tilly Herve, Huijgens Peter C., Kolstad Arne, d'Amore Francesco, Diaz Marcos Gonzalez, Petrini Mario, Sebban Catherine, Zinzani Pier Luigi, van Oers Marinus H. J., van Putten Wim, Bischof-Delaloye Angelika, Rohatiner Ama, Salles Gilles, Kuhlmann Jens, Hagenbeek Anton Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma Journal of clinical oncology 2008;26 (32):5156-5164 [PubMed]
• Vellenga Edo, van Putten Wim L. J., van 't Veer Mars B., Zijlstra Josée M., Fibbe Willem E., van Oers Marinus H. J., Verdonck Leo F., Wijermans Pierre W., van Imhoff Gustaaf W., Lugtenburg Pieternella J., Huijgens Peter C. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial Blood 2008;111 (2):537-543 [PubMed]
• Coiffier Bertrand, Lepretre Stéphane, Pedersen Lars Møller, Gadeberg Ole, Fredriksen Henrik, van Oers Marinus H. J., Wooldridge James, Kloczko Janusz, Holowiecki Jerzy, Hellmann Andrzej, Walewski Jan, Flensburg Mimi, Petersen Jørgen, Robak Tadeusz Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study Blood 2008;111 (3):1094-1100 [PubMed]
• van Beers Eduard J. Sickle cell disease, pathophysiology and clinical complications. 2008. 187p. ISBN 9789090233994. [UvA Dissertations Online] University of Amsterdam. (Supervisor: van Oers M. H. J.; Co-supervisors: Biemond B. J., Schnog J. B.)
• Mous Rogier Studies on the immune system in CLL. 2008. 165p. ISBN 9789088910623. [UvA Dissertations Online] University of Amsterdam. (Supervisors: van Oers M. H. J., van Lier R. A. W.; Co-supervisor: Eldering E. F.)
• Lokhorst Henk M., Schmidt-Wolf Ingo, Sonneveld Pieter, van der Holt Bronno, Martin Hans, Barge Rene, Bertsch Uta, Schlenzka Jana, Bos Gerard M. J., Croockewit Sandra, Zweegman Sonja, Breitkreuz Iris, Joosten Peter, Scheid Christof, van Marwijk-Kooy Marinus, Salwender Hans-Juergen, van Oers Marinus H. J., Schaafsma Ron, Naumann Ralph, Sinnige Harm, Blau Igor, Verhoef Gregor, de Weerdt Okke, Wijermans Pierre, Wittebol Shulamiet, Duersen Ulrich, Vellenga Edo, Goldschmidt Hartmut Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma Haematologica 2008;93 (1):124-127 [PubMed]
• Piriou Erwan, van Dort Karel, Otto Sigrid, van Oers Marinus H. J., van Baarle Debbie Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection Clinical infectious diseases 2008;46 (2):313-316 [PubMed]
• Gunn Shelly R., Mohammed Mansoor S., Gorre Mercedes E., Cotter Philip D., Kim Jaeweon, Bahler David W., Preobrazhensky Sergey N., Higgins Russell A., Bolla Aswani R., Ismail Sahar H., de Jong Daphne, Eldering Eric, van Oers Marinus H. J., Mellink Clemens H. M., Keating Michael J., Schlette Ellen J., Abruzzo Lynne V., Robetorye Ryan S. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia Journal of molecular diagnostics 2008;10 (5):442-451 [PubMed]

2007

• van Oosterwijk Michiel F., Juwana Hedi, Arens Ramon, Tesselaar Kiki, van Oers Marinus H. J., Eldering Eric, van Lier René A. W. CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development International immunology 2007;19 (6):713-718 [PubMed]
• Kater Arnon P., van Oers Marinus H. J., Kipps Thomas J. Cellular immune therapy for chronic lymphocytic leukemia Blood 2007;110 (8):2811-2818 [PubMed]
• Hallaert D. Y. H., Spijker R., Jak M., Derks I. A. M., Alves N. L., Wensveen F. M., de Boer J. P., de Jong D., Green S. R., van Oers M. H. J., Eldering E. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection Cell death and differentiation 2007;14 (11):1958-1967 [PubMed]
• Smit Laura A., Hallaert Delfine Y. H., Spijker René, de Goeij Bart, Jaspers Annelieke, Kater Arnon P., van Oers Marinus H. J., van Noesel Carel J. M., Eldering Eric Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity Blood 2007;109 (4):1660-1668 [PubMed]
• Sonneveld Pieter, van der Holt Bronno, Segeren Christine M., Vellenga Edo, Croockewit Alexandra J., Verhoe Gregor E. G., Cornelissen Jan J., Schaafsma Martijn R., van Oers Marinus H. J., Wijermans Pierre W., Westveer Petra H. M., Lokhorst Henk M. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial Haematologica 2007;92 (7):928-935 [PubMed]
• Bilgin Y. M., van de Watering L. M. G., Eijsman L., Versteegh M. I. M., van Oers M. H. J., Brand A. Is increased mortality associated with post-operative infections after leukocytes containing red blood cell transfusions in cardiac surgery? An extended analysis Transfusion medicine (Oxford, England) 2007;17 (4):304-311 [PubMed]
• Vermeulen M., van Oers M. H. J. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation Journal of neurology, neurosurgery, and psychiatry 2007;78 (10):1154 [PubMed]
• van Oers Marinus H. J. Rituximab maintenance in indolent lymphoma: indications and controversies Current oncology reports 2007;9 (5):378-383 [PubMed]
• van Oers Marinus H. J. Rituximab maintenance therapy: a step forward in follicular lymphoma Haematologica 2007;92 (6):826-833 [PubMed]
• de Heer K., Silbermann M. H., Koene H. R., Biemond B. J., Muller H. P., van Oers M. H. J. Systematische diagnostiek van erytrocytose Nederlands tijdschrift voor geneeskunde 2007;151 (32):1770-1776 [PubMed]
• Klein Saskia K., Biemond Bart J., van Oers Marinus H. J. Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA) Annals of hematology 2007;86 (12):917-918 [PubMed]

2006

• Wieland Catharina W., Kerver Marjolein E., Florquin Sandrine, Nolte Martijn A., Borst Jannie, van Lier Rene, van Oers Marinus H. J., van der Poll Tom CD27 contributes to the early systemic immune response to Mycobacterium tuberculosis infection but does not affect outcome International immunology 2006;18 (11):1531-1539 [PubMed]
• Piriou Erwan R. W. A. N., van Dort Karel, Weel Jan F. L., Bemelman Frederike J., Gamadia Laila E., van Oers Marinus H. J., van Baarle Debbie Detailed kinetics of EBV-specific CD4+ and CD8+ T cells during primary EBV infection in a kidney transplant patient Clinical immunology (Orlando, Fla.) 2006;119 (1):16-20 [PubMed]
• Linthorst G. E. Fabry disease revisted. Clinical and laboratory studies at the advent of enzyme supplementation therapy 2006. 297p. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Aerts J. M. F. G., van Oers M. H. J.; Co-supervisor: Hollak C. E. M.)
• Kater A. P. Novel apoptosis inducting strategies in chronic lymphocytic leukemia 2006. 208p. [UvA Dissertations Online] University of Amsterdam. (Supervisors: van Oers M. H. J., Kipps T. J.; Co-supervisor: Eldering E.)
• van de Donk N. W. C. J., Kröger N., Hegenbart U., Corradini P., San Miguel J. F., Goldschmidt H., Perez-Simon J. A., Zijlmans M., Raymakers R. A., Montefusco V., Ayuk F. A., van Oers M. H. J., Nagler A., Verdonck L. F., Lokhorst H. M. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma Bone marrow transplantation 2006;37 (12):1135-1141 [PubMed]
• Mous R., Savage P., Remmerswaal E. B. M., van Lier R. A. W., Eldering E., van Oers M. H. J. Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes Leukemia 2006;20 (6):1096-1102 [PubMed]
• van de Donk Niels W. C. J., Kröger Nicolaus, Hegenbart Ute, Corradini Paolo, San Miguel Jesus F., Goldschmidt Hartmut, Perez-Simon Jose A., Zijlmans Mark, Raymakers Reinier A., Montefusco Vittorio, Ayuk Francis A., van Oers Marinus H. J., Nagler Arnon, Verdonck Leo F., Lokhorst Henk M. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma Blood 2006;107 (8):3415-3416 [PubMed]
• Levi Marcel, Hack C. Erik, van Oers Marinus H. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency American journal of medicine 2006;119 (8):e3-e5 [PubMed]
• van Oers Marinus H. J., Klasa Richard, Marcus Robert E., Wolf Max, Kimby Eva, Gascoyne Randy D., Jack Andrew, van't Veer Mars, Vranovsky Andrej, Holte Harald, van Glabbeke Martine, Teodorovic Ivana, Rozewicz Cynthia, Hagenbeek Anton Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial Blood 2006;108 (10):3295-3301 [PubMed]

2005

• van Oers M. H. J. B-cel-chronische lymfatrische leukemie: risicostratificatie en behandeling Nederlands tijdschrift voor hematologie 2005;2 (4):132-139
• Bilgin Y. M., van de Watering L. M. G., Eijsman L., Versteegh M. I. M., van Oers M. H. J., Brand A. Bloedtransfusies en postoperatieve complicaties na hartklepchirurgie Hart Bulletin 2005;36 (4):108-112
• Mackus W. J. M., Kater A. P., Grummels A., Evers L. M., Hooijbrink B., Kramer M. H. H., Castro J. E., Kipps T. J., van Lier R. A. W., van Oers M. H. J., Eldering E. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation Leukemia 2005;19 (3):427-434 [PubMed]
• Kater A. P., van Oers M. H. J. Chronic lymphocytic leukemia: time for a risk-adapted approachin: R. M. Romero, editors. Trends in leukemia research. S.l.: Nova Science Publishers, Inc; 2005. p. 363-383, ISBN 9781594543111
• van Hulst M., Bilgin Y. M., van de Watering L. M. G., de Vries R., van Oers M. H. J., Brand A., Postma M. J. Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery Transfusion medicine (Oxford, England) 2005;15 (3):209-217 [PubMed]
• Arens Ramon, Baars Paul A., Jak Margot, Tesselaar Kiki, van der Valk Martin, van Oers Marinus H. J., van Lier René A. W. Cutting edge: CD95 maintains effector T cell homeostasis in chronic immune activation Journal of immunology (Baltimore, Md. 2005;174 (10):5915-5920 [PubMed]
• Juffermans N. P., Jager A., Kersten M. J., van Oers M. H., Hommes D. W. Epstein-Barr-virus-gerelateerde lymfomen bij patiënten met inflammatoire darmziekte Nederlands tijdschrift voor geneeskunde 2005;149 (33):1859-1863 [PubMed]
• Nolte Martijn A., Arens Ramon, van Os Ronald, van Oosterwijk Michiel, Hooibrink Berend, van Lier René A. W., van Oers Marinus H. J. Immune activation modulates hematopoiesis through interactions between CD27 and CD70 Nature immunology 2005;6 (4):412-418 [PubMed]
• Piriou Erwan, van Dort Karel, Nanlohy Nening M., van Oers Marinus H. J., Miedema Frank, van Baarle Debbie Loss of EBNA1-specific memory CD4(+) and CD8(+) T cells in HIV-infected patients progressing to AIDS-related non-hodgkin lymphoma Blood 2005;106 (9):3166-3174 [PubMed]
• Piriou Erwan R., van Dort Karel, Nanlohy Nening M., van Oers Marinus H., Miedema Frank, van Baarle Debbie Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects European journal of immunology 2005;35 (3):796-805 [PubMed]
• Piriou Erwan, Jansen Christine A., van Dort Karel, de Cuyper Iris, Nanlohy Nening M., Lange Joep M. A., van Oers Marinus H. J., Miedema Frank, van Baarle Debbie Reconstitution of EBV latent but not lytic antigen-specific CD4(+) and CD8(+) T cells after HIV treatment with highly active antiretroviral therapy Journal of immunology (Baltimore, Md. 2005;175 (3):2010-2017 [PubMed]
• Gallegos Ruiz M. I., van Oers M. H. J., Kersten M. J. Rituximab: de 'magic bullet' in de bestrijding van het B-cel-non-Hodgkin-lymfoom? Werkingsmechanismen en mogelijke oorzaken van resistentie Nederlands tijdschrift voor hematologie 2005;2 (5):184-191
• van Imhoff G. W., van der Holt B., MacKenzie M. A., Ossenkoppele G. J., Wijermans P. W., Kramer M. H. H., van 't Veer M. B., Schouten H. C., van Marwijk Kooy M., van Oers M. H. J., Raemaekers J. M. M., Sonneveld P., Meulendijks L. A. M. H., Kluin P. M., Kluin-Nelemans H. C., Verdonck L. F. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma Leukemia 2005;19 (6):945-952 [PubMed]
• Piriou E. Viro-immunoloy of EBV - HIV co-infection 2005. 136p. ISBN 9789090191553. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Miedema F., van Oers M. H. J.; Co-supervisor: van Baarle D.)

2004

• Piriou Erwan R., van Dort Karel, Nanlohy Nening M., Miedema Frank, van Oers Marinus H., van Baarle Debbie Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma Journal of immunology (Baltimore, Md. 2004;172 (11):6931-6937 [PubMed]
• Eldering Eric, Mackus Wendelina J. M., Derks Ingrid A. M., Evers Ludo M., Beuling Esther, Teeling Peter, Lens Susanne M. A., van Oers Marinus H. J., van Lier René A. W. Apoptosis via the B cell antigen receptor requires Bax translocation and involves mitochondrial depolarization, cytochrome C release, and caspase-9 activation European journal of immunology 2004;34 (7):1950-1960 [PubMed]
• Kater Arnon P., Remmerswaal Ester B. M., Nolte Martijn A., Eldering Eric, van Oers Marinus H. J., van Lier René A. W. Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia British journal of haematology 2004;126 (4):512-516 [PubMed]
• Nolte Martijn A., Arens Ramon, Kraus Manfred, van Oers Marinus H. J., Kraal Georg, van Lier René A. W., Mebius Reina E. B cells are crucial for both development and maintenance of the splenic marginal zone Journal of immunology (Baltimore, Md. 2004;172 (6):3620-3627 [PubMed]
• Kater Arnon P., Evers Ludo M., Remmerswaal Ester B. M., Jaspers Annelieke, Oosterwijk Michiel F., van Lier René A. W., van Oers Marinus H. J., Eldering Eric CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack British journal of haematology 2004;127 (4):404-415 [PubMed]
• Bilgin Y. M., van de Watering L. M. G., Eijsman L., Versteegh M. I. M., Brand R., van Oers M. H. J., Brand A. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery Circulation 2004;109 (22):2755-2760 [PubMed]
• Derksen Patrick W. B., Tjin Esther, Meijer Helen P., Klok Melanie D., MacGillavry Harold D., van Oers Marinus H. J., Lokhorst Henk M., Bloem Andries C., Clevers Hans, Nusse Roel, van der Neut Ronald, Spaargaren Marcel, Pals Steven T. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells Proceedings of the National Academy of Sciences of the United States of America 2004;101 (16):6122-6127 [PubMed]
• Arens Ramon, Nolte Martijn A., Tesselaar Kiki, Heemskerk Bianca, Reedquist Kris A., van Lier René A. W., van Oers Marinus H. J. Signaling through CD70 regulates B cell activation and IgG production Journal of immunology (Baltimore, Md. 2004;173 (6):3901-3908 [PubMed]
• Lokhorst Henk M., Wu Kalung, Verdonck Leo F., Laterveer Laurens L., van de Donk Niels W. C. J., van Oers Marinus H. J., Cornelissen Jan J., Schattenberg Anton V. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma Blood 2004;103 (11):4362-4364 [PubMed]
• Arens Ramon, Schepers Koen, Nolte Martijn A., van Oosterwijk Michiel F., van Lier René A. W., Schumacher Ton N. M., van Oers Marinus H. J. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation Journal of experimental medicine 2004;199 (11):1595-1605 [PubMed]

2003

• Mackus W. J. M. Antigen receptor triggering and apotopic pathways in neoplastic B cells 2003. 139p. ISBN 9789067340496. [UvA Dissertations Online] University of Amsterdam. (Supervisors: van Oers M. H. J., van Lier R. A. W.; Co-supervisor: Eldering E. F.)
• Arens R. Balancing effector lymphocyte formation via CD27-CD70 interactions 2003. 127p. [UvA Dissertations Online] University of Amsterdam. (Supervisors: van Lier R. A. W., van Oers M. H. J.)
• Doorduijn J. K., van der Holt B., van Imhoff G. W., van der Hem K. G., Kramer M. H. H., van Oers M. H. J., Ossenkoppele G. J., Schaafsma M. R., Verdonck L. F., Verhoef G. E. G., Steijaert M. M. C., Buijt I., Uyl-de Groot C. A., van Agthoven M., Mulder A. H., Sonneveld P. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma Journal of clinical oncology 2003;21 (16):3041-3050 [PubMed]
• Kater A. P., van Oers M. H. J. Chronische lymfatische leukemie: hoog tijd voor een op het risico afgestemd beleid Nederlands tijdschrift voor geneeskunde 2003;147 (3):104-110 [PubMed]
• Mackus Wendelina J. M., Frakking Florine N. J., Grummels Annette, Gamadia Laila E., de Bree Godelieve J., Hamann Dorte, van Lier Rene A. W., van Oers Marinus H. J. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia Blood 2003;102 (3):1057-1063 [PubMed]
• Haas R. L. M., Poortmans Ph, de Jong D., Aleman B. M. P., Dewit L. G. H., Verheij M., Hart A. A. M., van Oers M. H. J., van der Hulst M., Baars J. W., Bartelink H. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas Journal of clinical oncology 2003;21 (13):2474-2480 [PubMed]
• Tesselaar Kiki, Arens Ramon, van Schijndel Gijs M. W., Baars Paul A., van der Valk Martin A., Borst Jannie, van Oers Marinus H. J., van Lier René A. W. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions Nature immunology 2003;4 (1):49-54 [PubMed]
• Bollen J. M., Polstra A. M., van der Kuyl A. C., Weel J. F., Noorduyn L. A., van Oers M. H. J., Cornelissen M. Multicentric Castleman's disease and Kaposi's sarcoma in a cyclosporin treated, HIV-1 negative patient: case report BMC blood disorders 2003;3 (1):3 [PubMed]
• Segeren Christine M., Sonneveld Pieter, van der Holt Bronno, Vellenga Edo, Croockewit Alexandra J., Verhoef Gregor E. G., Cornelissen Jan J., Schaafsma Martijn R., van Oers Marinus H. J., Wijermans Pierre W., Fibbe Wim E., Wittebol Shulamit, Schouten Harry C., van Marwijk Kooy Marinus, Biesma Douwe H., Baars Joke W., Slater Rosalyn, Steijaert Monique M. C., Buijt Ivon, Lokhorst Henk M. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study Blood 2003;101 (6):2144-2151 [PubMed]
• Lokhorst Henk M., Segeren Christine M., Verdonck Leo F., van der Holt Bronno, Raymakers Reinier, van Oers Marinus H. J., Barge Renee M. Y., Schouten Harry C., Westveer Petra H. M., Steijaert Monique M. C., Cornelissen Jan J., Sonneveld Pieter Partially T-Cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: A prospective evaluation of patients treated in the phase III study HOVON 24 MM Journal of clinical oncology 2003;21 (9):1728-1733 [PubMed]
• van der Kolk L. E., Grillo-López A. J., Baars J. W., van Oers M. H. J. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy Leukemia 2003;17 (8):1658-1664 [PubMed]

2002

• van Baarle Debbie, Wolthers Katja C., Hovenkamp Egbert, Niesters Hubert G. M., Osterhaus Albert D. M. E., Miedema Frank, van Oers Marinus H. J. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma Journal of infectious diseases 2002;186 (3):405-409 [PubMed]
• van der Kolk L. E., de Haas M., Grillo-López A. J., Baars J. W., van Oers M. H. J. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils Leukemia 2002;16 (4):693-699 [PubMed]
• van der Vliet H. J. J., van Oers M. H. J., Schot L. J., Majoie C. B. L., van der Meer J. T. M. A space-occupying lesion of the skull base, masked by nasopharyngeal lymphatic tissue hypertrophy and causing cranial nerve dysfunction in an HIV-infected patient Annals of hematology 2002;81 (3):164-166 [PubMed]
• van der Kolk L. E., Evers L. M., Omene C., Lens S. M. A., Lederman S., van Lier R. A. W., van Oers M. H. J., Eldering E. CD20-induced B cell death can bypass mitochondria and caspase activation Leukemia 2002;16 (9):1735-1744 [PubMed]
• Derksen Patrick W. B., Keehnen Robert M. J., Evers Ludo M., van Oers Marinus H. J., Spaargaren Marcel, Pals Steven T. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma Blood 2002;99 (4):1405-1410 [PubMed]
• van Oers M. H. J., Hagenbeek A., van Glabbeke M., Teodorovic I. Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial - Intergroup Collaborative Study Annals of hematology 2002;81 (10):553-557 [PubMed]
• van Lier R. A. W., van Oers M. J. H. Curtailing BCR signaling Blood 2002;100 (9):3061
• van Baarle Debbie, Kostense Stefan, van Oers Marinus H. J., Hamann Dorte, Miedema Frank Failing immune control as a result of impaired CD8(+) T-cell maturation: CD27 might provide a clue Trends in immunology 2002;23 (12):586-591 [PubMed]
• Kostense Stefan, Otto Sigrid A., Knol Gerlinde J., Manting Erik H., Nanlohy Nening M., Jansen Christine, Lange Joep M. A., van Oers Marinus H. J., Miedema Frank, van Baarle Debbie Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells European journal of immunology 2002;32 (4):1080-1089 [PubMed]
• Kater A. P., van Oers M. H. J. Immunogentherapie. Bestrijding leukemie door activatie afweersysteem met behulp van CD70 Analyse (Amsterdam) 2002 (oktober):240-242
• van Baarle Debbie, Kostense Stefan, Hovenkamp Egbert, Ogg Graham, Nanlohy Nening, Callan Margaret F. C., Dukers Nicole H. T. M., McMichael Andrew J., van Oers Marinus H. J., Miedema Frank Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection AIDS (London, England) 2002;16 (15):2001-2011 [PubMed]
• Mackus Wendelina J. M., Lens Susanne M. A., Medema René H., Kwakkenbos Mark J., Evers Ludo M., Oers Marinus H. J. van, van Lier René A. W., Eldering Eric Prevention of B cell antigen receptor-induced apoptosis by ligation of CD40 occurs downstream of cell cycle regulation International immunology 2002;14 (9):973-982 [PubMed]
• van der Kolk Lizet E., Baars Joke W., Prins Martin H., van Oers Marinus H. J. Rituximab treatment results in impaired secondary humoral immune responsiveness Blood 2002;100 (6):2257-2259 [PubMed]
• Vermeulen M., van Oers M. H. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy Journal of neurology, neurosurgery, and psychiatry 2002;72 (1):127-128 [PubMed]

2001

• Vellenga E., van Agthoven M., Croockewit A. J., Verdonck L. F., Wijermans P. J., van Oers M. H., Volkers C. P., van Imhoff G. W., Kingma T., Uyl-de Groot C. A., Fibbe W. E. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study British journal of haematology 2001;114 (2):319-326 [PubMed]
• van der Kolk L. E., Grillo-López A. J., Baars J. W., Hack C. E., van Oers M. H. Complement activation plays a key role in the side-effects of rituximab treatment British journal of haematology 2001;115 (4):807-811 [PubMed]
• Arens R., Tesselaar K., Baars P. A., van Schijndel G. M., Hendriks J., Pals S. T., Krimpenfort P., Borst J., van Oers M. H., van Lier R. A. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion Immunity 2001;15 (5):801-812 [PubMed]
• van der Lelie J., van Oers M. H., von dem Borne A. E. De diagnostiek van anemie Nederlands tijdschrift voor geneeskunde 2001;145 (18):866-869 [PubMed]
• van Baarle D., Hovenkamp E., Callan M. F., Wolthers K. C., Kostense S., Tan L. C., Niesters H. G., Osterhaus A. D., McMichael A. J., van Oers M. H., Miedema F. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma Blood 2001;98 (1):146-155 [PubMed]
• van der Lelie H., Thomas B. L., van Oers R. H., Ek-Post M., Sjamsoedin S. A., van Dijk-Overtoom M. L., Timmer J. G., von dem Borne A. E. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study Annals of hematology 2001;80 (3):150-154 [PubMed]
• Kersten M. J., van Oers R. H. Management of AIDS-related non-Hodgkin's lymphomas Drugs 2001;61 (9):1301-1315 [PubMed]
• de Jong M. D., Weel J. F., van Oers M. H., Boom R., Wertheim-van Dillen P. M. Molecular diagnosis of visceral herpes zoster Lancet 2001;357 (9274):2101-2102 [PubMed]

2000

• Nurmohamed M. T., Soesan M., van Oers M. H., Dijkmans B. A., van Soesbergen R. M. Cyclosporin for sulphasalazine-induced aplastic anaemia in a patient with early rheumatoid arthritis Rheumatology (Oxford, England) 2000;39 (12):1431-1433 [PubMed]
• Lokhorst H. M., Schattenberg A., Cornelissen J. J., van Oers M. H., Fibbe W., Russell I., Donk N. W., Verdonck L. F. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome Journal of clinical oncology 2000;18 (16):3031-3037 [PubMed]
• van Baarle D., Hovenkamp E., Dukers N. H., Renwick N., Kersten M. J., Goudsmit J., Coutinho R. A., Miedema F., van Oers M. H. High prevalence of Epstein-Barr virus type 2 among homosexual men is caused by sexual transmission Journal of infectious diseases 2000;181 (6):2045-2049 [PubMed]
• Merkus P., Copper M. P., van Oers M. H., Schouwenburg P. F. Lymphoma in the ear ORL; journal for oto-rhino-laryngology and its related specialties 2000;62 (5):274-277 [PubMed]

1999

• Lens S. M., Drillenburg P., den Drijver B. F., van Schijndel G., Pals S. T., van Lier R. A., van Oers M. H. Aberrant expression and reverse signalling of CD70 on malignant B cells British journal of haematology 1999;106 (2):491-503 [PubMed]
• Berger C., van Baarle D., Kersten M. J., Klein M. R., Al-Homsi A. S., Dunn B., McQuain C., van Oers R., Knecht H. Carboxy terminal variants of Epstein-Barr virus-encoded latent membrane protein 1 during long-term human immunodeficiency virus infection: reliable markers for individual strain identification Journal of infectious diseases 1999;179 (1):240-244 [PubMed]
• van Baarle D., Hovenkamp E., Kersten M. J., Klein M. R., Miedema F., van Oers M. H. Direct Epstein-Barr virus (EBV) typing on peripheral blood mononuclear cells: no association between EBV type 2 infection or superinfection and the development of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma Blood 1999;93 (11):3949-3955 [PubMed]
• Kersten M. J., Surachno S., Koopman M. G., van 't Veer L. J., Pals S. T., van Oers M. H. Epstein-Barr-virus in een donornier als oorzaak van non-Hodgkin-lymfoom Nederlands tijdschrift voor geneeskunde 1999;143 (7):360-364 [PubMed]
• Lokhorst H. M., Sonneveld P., Cornelissen J. J., Joosten P., van Marwijk Kooy M., Meinema J., Nieuwenhuis H. K., van Oers M. H., Richel D. J., Segeren C. N., Veth G., Verdonck L. F., Wijermans P. W. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma Bone marrow transplantation 1999;23 (4):317-322 [PubMed]
• Segeren C. M., Sonneveld P., van der Holt B., Baars J. W., Biesma D. H., Cornellissen J. J., Croockewit A. J., Dekker A. W., Fibbe W. E., Löwenberg B., van Marwijk Kooy M., van Oers M. H., Richel D. J., Schouten H. C., Vellenga E., Verhoef G. E., Wijermans P. W., Wittebol S., Lokhorst H. M. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma British journal of haematology 1999;105 (1):127-130 [PubMed]

1998

• Hollak C. E., Aerts J. M., van Oers M. H. Alglucerase: practical guidance on appropriate dosage and administration in patients with Gaucher disease BioDrugs 1998;9 (1):11-23 [PubMed]
• van Zaanen H. C., Lokhorst H. M., Aarden L. A., Rensink H. J., Warnaar S. O., van Oers M. H. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130 Leukemia & lymphoma 1998;31 (5-6):551-558 [PubMed]
• van Zaanen H. C., Lokhorst H. M., Aarden L. A., Rensink H. J., Warnaar S. O., van der Lelie J., van Oers M. H. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study British journal of haematology 1998;102 (3):783-790 [PubMed]
• Lens S. M., Tesselaar K., van Oers M. H., van Lier R. A. Control of lymphocyte function through CD27-CD70 interactions Seminars in immunology 1998;10 (6):491-499 [PubMed]
• Lens S. M., den Drijver B. F., Pötgens A. J., Tesselaar K., van Oers M. H., van Lier R. A. Dissection of pathways leading to antigen receptor-induced and Fas/CD95-induced apoptosis in human B cells Journal of immunology (Baltimore, Md. 1998;160 (12):6083-6092 [PubMed]
• Kersten M. J., van Gorp J., Pals S. T., Boon F., van Oers M. H. Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin's lymphomas: correlation with histology and CD4-cell number Leukemia & lymphoma 1998;30 (5-6):515-524 [PubMed]
• Al-Homsi A. S., Berger C., van Baarle D., Kersten M. J., Klein M. R., McQuain C., van Oers R., Knecht H. Molecular analysis of critical sequences within the EBNA-2 type 1 gene from Epstein-Barr virus isolates from patients with infectious mononucleosis, tonsillar hyperplasia, and HIV infection International journal of molecular medicine 1998;1 (6):983-987 [PubMed]
• Venema D., Schut M., van Oers M. H. Richtlijnen voor het gebruik van vers bevroren plasma suboptimaal nageleefd Nederlands tijdschrift voor geneeskunde 1998;142 (36):1999-2002 [PubMed]
• Kersten M. J., Verduyn T. J., Reiss P., Evers L. M., de Wolf F., van Oers M. H. Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: clinical outcome and effect on HIV-1 viral load Annals of oncology 1998;9 (10):1135-1138 [PubMed]

1997

• Kersten M. J., de Jong S., Evers L. M., Koene H. R., van Oers M. H. Addition of granulocyte colony-stimulating factor to chemotherapy in patients with AIDS-related lymphoma: effects on neutrophil Fc gamma receptor expression and soluble Fc gammaRIII plasma levels British journal of haematology 1997;99 (3):537-541 [PubMed]
• Lens S. M., Baars P. A., Hooibrink B., van Oers M. H., van Lier R. A. Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells Immunology 1997;90 (1):38-45 [PubMed]
• Hollak C. E., Levi M. [=Marcel M.], Berends F., Aerts J. M., van Oers M. H. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy British journal of haematology 1997;96 (3):470-476 [PubMed]
• Hollak C. E., Corssmit E. P., Aerts J. M., Endert E., Sauerwein H. P., Romijn J. A., van Oers M. H. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease American journal of medicine 1997;103 (3):185-191 [PubMed]
• Hollak C. E., Evers L., Aerts J. M., van Oers M. H. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease Blood cells, molecules & diseases 1997;23 (2):201-212 [PubMed]
• Kersten M. J., Klein M. R., Holwerda A. M., Miedema F., van Oers M. H. Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma Journal of clinical investigation 1997;99 (7):1525-1533 [PubMed]
• Boot R. G., Hollak C. E., Verhoek M., Sloof P., Poorthuis B. J., Kleijer W. J., Wevers R. A., van Oers M. H., Mannens M. M., Aerts J. M., van Weely S. Glucocerebrosidase genotype of Gaucher patients in The Netherlands: limitations in prognostic value Human mutation 1997;10 (5):348-358 [PubMed]
• Vrielink H., Reésink H. W., Zaaijer H. L., Scholten E., Kremer L. C., Cuypers H. T., Lelie P. N., van Oers M. H., van der Poel C. L. Look-back of anti-HCV ELISA-positive, HCV-RNA PCR-negative donors and recipients of their blood products Vox sanguinis 1997;72 (2):67-70 [PubMed]
• van Zaanen H. C., Romijn J. A., Sauerwein H. P., Lokhorst H. M., Warnaar S. O., Aarden L. A., Endert E., van Oers M. H. Modulation of chronic excessive interleukin-6 production in multiple myeloma does not affect thyroid hormone concentrations Metabolism: clinical and experimental 1997;46 (11):1343-1348 [PubMed]
• van der Lelie J., Venema D., Kuijper E. J., van Steenwijk R. P., van Oers M. H., Thomas L. L., von dem Borne A. E. Pneumocystis carinii pneumonia in HIV-negative patients with haematologic disease Infection 1997;25 (2):78-81 [PubMed]

1996

• Vervoordeldonk S. F., Heikens J., Goedemans W. T., Merle P. A., von dem Borne A. E., van Royen E. A., Slaper-Cortenbach I. C., van Oers R. H. 99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphoma Cancer immunology, immunotherapy 1996;42 (5):291-296 [PubMed]
• van der Lelie J., Louwerse E. S., Thomas L. L., van Oers M. H., von dem Borne A. E. Acute ischaemic cerebrovascular accident after autologous bone marrow transplantation European journal of haematology 1996;56 (1-2):95-97 [PubMed]
• Lens S. M., Tesselaar K., den Drijver B. F., van Oers M. H., van Lier R. A. A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death Journal of immunology (Baltimore, Md. 1996;156 (2):507-514 [PubMed]
• Lankester A. C., Schijndel G. M., Pakker N. G., van Oers R. H., van Lier R. A. Antigen receptor function in chronic lymphocytic leukemia B cells Leukemia & lymphoma 1996;24 (1-2):27-33 [PubMed]
• van Pelt L. J., Huisman M. V., Weening R. S., von dem Borne A. E., Roos D., van Oers R. H. A single dose of granulocyte-macrophage colony-stimulating factor induces systemic interleukin-8 release and neutrophil activation in healthy volunteers Blood 1996;87 (12):5305-5313 [PubMed]
• Hollak C. E., van Oers M. H., Maaswinkel P., Aerts J. M., Goudsmit R. Behandeling van de ziekte van Gaucher in Nederland met enzymvervangingstherapie Nederlands tijdschrift voor geneeskunde 1996;140 (19):1011-1013 [PubMed]
• Kersten M. J., Evers L. M., Dellemijn P. L., van den Berg H., Portegies P., Hintzen R. Q., van Lier R. A., von dem Borne A. E., van Oers R. H. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies Blood 1996;87 (5):1985-1989 [PubMed]
• van Zaanen H. C., Koopmans R. P., Aarden L. A., Rensink H. J., Stouthard J. M., Warnaar S. O., Lokhorst H. M., van Oers M. H. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop Journal of clinical investigation 1996;98 (6):1441-1448 [PubMed]
• Hollak C. E. M. Gaucher Disease. Clinical and laboratory studies in relation to enzyme supplementation therapy. 1996. 218p. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Goudsmit R., von dem Borne A. E. G. K.; Co-supervisors: van Oers M. H. J., Aerts J. M. F. G.)
• Lens S. M., Keehnen R. M., van Oers M. H., van Lier R. A., Pals S. T., Koopman G. Identification of a novel subpopulation of germinal center B cells characterized by expression of IgD and CD70 European journal of immunology 1996;26 (5):1007-1011 [PubMed]
• Lokhorst H. M., Sonneveld P., Wijermans P. W., van Marwijk Kooy M., Meuwissen O. J., van Oers R. H., van der Griend R., Dekker A. W. Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma British journal of haematology 1996;92 (1):44-48 [PubMed]
• Hollak C. E., Goudsmit R., van Oers M. H. Low-dose versus high-frequency regimens in Gaucher's disease Lancet 1996;347 (8998):406-407 [PubMed]
• Lens S. M., de Jong R., Hooibrink B., Koopman G., Pals S. T., van Oers M. H., van Lier R. A. Phenotype and function of human B cells expressing CD70 (CD27 ligand) European journal of immunology 1996;26 (12):2964-2971 [PubMed]
• Michelakakis H., Spanou C., Kondyli A., Dimitriou E., van Weely S., Hollak C. E., van Oers M. H., Aerts J. M. Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE 1996;1317 (3):219-222 [PubMed]
• Consten E. C., Henny C. P., Eijsman L., Dongelmans D. A., van Oers M. H. The routine use of fresh frozen plasma in operations with cardiopulmonary bypass is not justified Journal of thoracic and cardiovascular surgery 1996;112 (1):162-167 [PubMed]

1995

• Lankester A. C., van Schijndel G. M., van der Schoot C. E., van Oers M. H., van Noesel C. J., van Lier R. A. Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells Blood 1995;86 (3):1090-1097 [PubMed]
• van Zaanen H. C., Vet R. J., de Jong C. M., von dem Borne A. E., van Oers M. H. A simple and sensitive method for determining plasma cell isotype and monoclonality in bone marrow using flowcytometry British journal of haematology 1995;91 (1):55-59 [PubMed]
• Lens S. M., de Jong R., Hintzen R. Q., Koopman G., van Lier R. A., van Oers R. H. CD27-CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth Leukemia & lymphoma 1995;18 (1-2):51-59 [PubMed]
• Verdonck L. F., van Putten W. L., Hagenbeek A., Schouten H. C., Sonneveld P., van Imhoff G. W., Kluin-Nelemans H. C., Raemaekers J. M., van Oers R. H., Haak H. L. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma New England journal of medicine 1995;332 (16):1045-1051 [PubMed]
• van der Lelie H., Leverstein-van Hall M., Mertens M., van Zaanen H. C., van Oers R. H., Thomas B. L., von dem Borne A. E., Kuijper E. J. Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and a systematic literature review Scandinavian journal of infectious diseases 1995;27 (6):581-584 [PubMed]
• van der Lelie H., Baars J. W., Rodenhuis S., Van Dijk M. A., de Glas-Vos C. W., Thomas B. L., van Oers R. H., von dem Borne A. E. Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support Cancer 1995;76 (11):2338-2342 [PubMed]
• Corssmit E. P., Hollak C. E., Endert E., van Oers M. H., Sauerwein H. P., Romijn J. A. Increased basal glucose production in type 1 Gaucher's disease Journal of clinical endocrinology and metabolism 1995;80 (9):2653-2657 [PubMed]
• Hollak C. E., Aerts J. M., Goudsmit R., Phoa S. S., Ek M., van Weely S., von dem Borne A. E., van Oers M. H. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease Lancet 1995;345 (8963):1474-1478 [PubMed]
• Vrielink H., van der Poel C. L., Reesink H. W., Zaaijer H. L., Scholten E., Kremer L. C., Cuypers H. T., Lelie P. N., van Oers M. H. Look-back study of infectivity of anti-HCV ELISA-positive blood components Lancet 1995;345 (8942):95-96 [PubMed]
• Aerts J. M. F. G., Boot R. G., Renkema G. H., van Weely S., Jones S., Hollak C. E. M., van Oers M. H. J. Molecular and biochemical abnormalities of Gaucher disease. Chitotriosidase, a newly identified biochemical marker. Seminars in hematology 1995;32 (suppl. 1):10-13

1994

• Koopman G., Reutelingsperger C. P., Kuijten G. A., Keehnen R. M., Pals S. T., van Oers M. H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis Blood 1994;84 (5):1415-1420 [PubMed]
• de Haas M., Kerst J. M., van der Schoot C. E., Calafat J., Hack C. E., Nuijens J. H., Roos D., van Oers R. H., von dem Borne A. E. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils Blood 1994;84 (11):3885-3894 [PubMed]
• Hollak C. E., van Weely S., van Oers M. H., Aerts J. M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease Journal of clinical investigation 1994;93 (3):1288-1292 [PubMed]
• Lokhorst H. M., Lamme T., de Smet M., Klein S., de Weger R. A., van Oers R., Bloem A. C. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures Blood 1994;84 (7):2269-2277 [PubMed]
• Huizinga T. W., de Haas M., van Oers M. H., Kleijer M., Vilé H., van der Wouw P. A., Moulijn A., van Weezel H., Roos D., von dem Borne A. E. The plasma concentration of soluble Fc-gamma RIII is related to production of neutrophils British journal of haematology 1994;87 (3):459-463 [PubMed]

1993

• Kerst J. M., Sanders J. B., Slaper-Cortenbach I. C., Doorakkers M. C., Hooibrink B., van Oers R. H., von dem Borne A. E., van der Schoot C. E. Alpha 4 beta 1 and alpha 5 beta 1 are differentially expressed during myelopoiesis and mediate the adherence of human CD34+ cells to fibronectin in an activation-dependent way Blood 1993;81 (2):344-351 [PubMed]
• van Kooten C., Rensink I., Aarden L., van Oers R. Cytokines and intracellular signals involved in the regulation of B-CLL proliferation Leukemia & lymphoma 1993;12 (1-2):27-33 [PubMed]
• van Kooten C., Rensink I., Aarden L., van Oers R. Differentiation of purified malignant B cells induced by PMA or by activated normal T cells Leukemia 1993;7 (10):1576-1584 [PubMed]
• van Kooten C., Rensink I., Aarden L., van Oers R. Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells Leukemia 1993;7 (4):618-624 [PubMed]
• Hollak C. E. M., Aerts J. M. F. G., van Oers M. H. J. Enzyme replacement therapy for type 1 Gaucher disease: experience with low-dose schedules of alglucerase Gaucher clinical perspectives 1993;1:12-13
• van Oers M. H., Pals S. T., Evers L. M., van der Schoot C. E., Koopman G., Bonfrer J. M., Hintzen R. Q., von dem Borne A. E., van Lier R. A. Expression and release of CD27 in human B-cell malignancies Blood 1993;82 (11):3430-3436 [PubMed]
• Kerst J. M., van de Winkel J. G., Evans A. H., de Haas M., Slaper-Cortenbach I. C., de Wit T. P., von dem Borne A. E., van der Schoot C. E., van Oers R. H. Granulocyte colony-stimulating factor induces hFc gamma RI (CD64 antigen)-positive neutrophils via an effect on myeloid precursor cells Blood 1993;81 (6):1457-1464 [PubMed]
• Zimran A., Hollak C. E., Abrahamov A., van Oers M. H., Kelly M., Beutler E. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients Blood 1993;82 (4):1107-1109 [PubMed]
• van Oers M. H., van Zaanen H. C., Lokhorst H. M. Interleukin-6, a new target for therapy in multiple myeloma? Annals of hematology 1993;66 (5):219-223 [PubMed]
• Kerst J. M., Slaper-Cortenbach I. C., van der Schoot C. E., Hooibrink B., von dem Borne A. E., van Oers R. H. Interleukin-6 is a survival factor for committed myeloid progenitor cells Experimental hematology 1993;21 (12):1550-1557 [PubMed]
• Schut N. H., Wiersinga W. M., van Oers M. H. Methimazole-induced agranulocytosis preceded by transient granulocytopenia. A case report Netherlands journal of medicine 1993;43 (1-2):71-73 [PubMed]
• Kersten M. J., Mertens M. J., Pals S. T., Reiss P., van Oers M. H. Met HIV samenhangend non-Hodgkin-lymfoom bij 45 patiënten; een retrospectieve analyse Nederlands tijdschrift voor geneeskunde 1993;137 (28):1396-1400 [PubMed]
• Leeksma O. C., van Oers M. H., van der Schoot C. E., Goudsmit R., von dem Borne A. E. Primaire behandeling van acute promyelocytenleukemie met all-trans-retinoïnezuur Nederlands tijdschrift voor geneeskunde 1993;137 (16):821-825 [PubMed]
• Kerst J. M., de Haas M., van der Schoot C. E., Slaper-Cortenbach I. C., Kleijer M., von dem Borne A. E., van Oers R. H. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells Blood 1993;82 (11):3265-3272 [PubMed]
• van Kooten C., Rensink I., Aarden L., van Oers R. TNF-alpha induces spreading of B-CLL via the CD11c/CD18 molecule American journal of hematology 1993;44 (4):221-228 [PubMed]
• Hollak C. E., Aerts J. M., van Oers M. H. Treatment of Gaucher's disease New England journal of medicine 1993;328 (21):1565-6; author reply 1567 [PubMed]

1992

• van der Beek-Boter J. W., van Oers M. H., von dem Borne A. E., Klaassen R. J. Ascorbate for the treatment of ITP European journal of haematology 1992;48 (1):61-62 [PubMed]
• van Kooten C., van der Pouw Kraan T., Rensink I., van Oers R., Aarden L. Both naive and memory T cells can provide help for human IgE production, but with different cytokine requirements European cytokine network 1992;3 (3):289-297 [PubMed]
• Kerst J. M., Slaper-Cortenbach I. C., von dem Borne A. E., van der Schoot C. E., van Oers R. H. Combined measurement of growth and differentiation in suspension cultures of purified human CD34-positive cells enables a detailed analysis of myelopoiesis Experimental hematology 1992;20 (10):1188-1193 [PubMed]
• Leeksma O. C., Thomas L. L., van der Lelie J., van Oers M. H., von dem Borne A. E., Goudsmit R. Effectiveness of low dose cyclosporine in acquired aplastic anaemia with severe neutropenia Netherlands journal of medicine 1992;41 (3-4):143-148 [PubMed]
• van Kooten C., Rensink I., Aarden L., van Oers R. Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-alpha-induced proliferation of B chronic lymphocytic leukemia cells Blood 1992;80 (5):1299-1306 [PubMed]
• Tusenius K. J., Bakker P. J., van Oers M. H. Measurement of proliferation indices in non Hodgkin's lymphoma--is it useful? Leukemia & lymphoma 1992;7 (3):181-187 [PubMed]

1991

• van der Wouw P. A., van Leeuwen R., van Oers R. H., Lange J. M., Danner S. A. Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study British journal of haematology 1991;78 (3):319-324 [PubMed]
• van der Pouw-Kraan T., van Kooten C., van Oers R., Aarden L. A. Human transferrin allows efficient IgE production by anti-CD3-stimulated human lymphocytes at low cell densities European journal of immunology 1991;21 (2):385-390 [PubMed]
• van der Lelie H., van Ketel R. J., von dem Borne A. E., van Oers R. H., Thomas B. L., Goudsmit R. Incidence and clinical epidemiology of streptococcal septicemia during treatment of acute myeloid leukemia Scandinavian journal of infectious diseases 1991;23 (2):163-168 [PubMed]
• van Kooten C., Rensink I., Pascual-Salcedo D., van Oers R., Aarden L. Monokine production by human T cells; IL-1 alpha production restricted to memory T cells Journal of immunology (Baltimore, Md. 1991;146 (8):2654-2658 [PubMed]

1990

• von dem Borne A. E., van Oers R. H., Wiersinga W. M., van der Tweel J. G. Complete remission of autoimmune thrombocytopenia after extirpation of a benign adenofibroma of the ovary British journal of haematology 1990;74 (1):119-120 [PubMed]
• Schuitemaker H., Kootstra N. A., van Oers M. H., van Lambalgen R., Tersmette M., Miedema F. Induction of monocyte proliferation and HIV expression by IL-3 does not interfere with anti-viral activity of zidovudine Blood 1990;76 (8):1490-1493 [PubMed]
• van Kooten C., van Oers M. H., Aarden L. A. Interleukin-6 enhances human Ig production, but not as a terminal differentiation factor for B lymphocytes Research in immunology 1990;141 (4-5):341-356 [PubMed]

1989

• van der Schoot C. E., Jansen P., Poorter M., Wester M. R., von dem Borne A. E., Aarden L. A., van Oers R. H. Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation Blood 1989;74 (6):2081-2087 [PubMed]
• Bloemena E., van Lier R. A., van Oers M. H., Weinreich S., Stilma-Meinesz A. P., Schellekens P. T. The effects of prednisolone and cyclosporin A on monocyte-dependent and -independent human T-cell proliferation in vitro Transplantation proceedings 1989;21 (1 Part 1):861-865 [PubMed]
• Bloemena E., van Oers R. H., Weinreich S., Stilma-Meinesz A. P., Schellekens P. T., van Lier R. A. The influence of cyclosporin A on the alternative pathways of human T cell activation in vitro European journal of immunology 1989;19 (5):943-946 [PubMed]
• van der Heyden A. A., Bloemena E., Out T. A., Wilmink J. M., Schellekens P. T., van Oers M. H. The influence of immunosuppressive treatment on immune responsiveness in vivo in kidney transplant recipients Transplantation 1989;48 (1):44-47 [PubMed]

1988

• Haeck J., Frissen P. H., van Oers M. H. AIDS en non-Hodgkinlymfoom, een verraderlijke combinatie Nederlands tijdschrift voor geneeskunde 1988;132 (36):1669-1671 [PubMed]
• Bloemena E., van Oers M. H., Weinreich S., Schellekens P. T. Cyclosporin A and prednisolone do not inhibit the expression of high-affinity receptors for interleukin 2 Clinical and experimental immunology 1988;71 (2):308-313 [PubMed]
• Bloemena E., van Oers M. H., Weinreich S., Yong S. L., Schellekens P. T. Cyclosporine A does not prevent expression of biologically active IL 2 receptors in vitro Transplantation proceedings 1988;20 (2 Suppl 2):131-135 [PubMed]
• van Oers M. H., van der Heyden A. A., Aarden L. A. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients Clinical and experimental immunology 1988;71 (2):314-319 [PubMed]
• Bloemena E., van Oers M. H., Weinreich S., Yong S. L., Schellekens P. T. Prednisolone and cyclosporin A exert differential inhibitory effects on T-cell proliferation in vitro Clinical immunology and immunopathology 1988;48 (3):380-391 [PubMed]
• Pietersz R. N., Reesink H. W., Huijgens P. C., van Oers M. H. Preparation of leucocyte-poor platelet concentrates from buffy coats. IV. Clinical evaluation Vox sanguinis 1988;55 (3):129-132 [PubMed]
• van der Heyden A. A., van Oers M. H., Cornelissen P., Yong S. L., Wilmink J. M., Schellekens P. T. The influence of cyclosporine A treatment on immune responsiveness in vitro and in vivo in kidney transplant recipients Transplantation proceedings 1988;20 (2 Suppl 2):190-195 [PubMed]
• Boucher C. A., de Gans J., van Oers R., Danner S., Goudsmit J. Transmission of HIV and AIDS by plasmapheresis for Guillain-Barré syndrome Clinical neurology and neurosurgery 1988;90 (3):235-236 [PubMed]
• van der Poel C. L., Reesink H. W., van Oers M. H., van der Meulen F. W. Transmission of HIV by transfusion of ELISA-negative blood Vox sanguinis 1988;54 (4):247 [PubMed]

1987

• van Oers M. H., Surachno S., Wilmink J. M. Infiltrate analysis by monoclonal antibodies does not contribute to the usefulness of fine needle aspiration biopsy Transplantation proceedings 1987;19 (1 Part 2):1646-1649 [PubMed]

1986

• Surachno S., van Oers M. H., Wilmink J. M. Early diagnosis of bacterial infection of renal allografts by fine needle aspiration biopsy Lancet 1986;1 (8482):686-687 [PubMed]

1984

• van Oers M. H., ten Veen J. H. Is ciclosporine een aanwinst bij niertransplantaties? Nederlands tijdschrift voor geneeskunde 1984;128 (22):1058-1061 [PubMed]
• Stam J., van Oers M. H., Verbeeten B. Recovery after central pontine myelinolysis Journal of neurology 1984;231 (1):52-53 [PubMed]

1980

• Bom-van Noorloos A. A., Pegels H. G., van Oers R. H., Silberbusch J., Feltkamp-Vroom T. M., Goudsmit R., Zeijlemaker W. P., von dem Borne A. E., Melief C. J. Proliferation of T gamma cells with killer-cell activity in two patients with neutropenia and recurrent infections New England journal of medicine 1980;302 (17):933-937 [PubMed]

1979

• van Oers M. H., Pinkster J., Zeijlemaker W. P. Cooperative effects in mitogen- and antigen-induced responses of human peripheral blood lymphocyte subpopulations International archives of allergy and applied immunology 1979;58 (1):53-66 [PubMed]

1978

• van Oers M. H., de Goede R. E., Zeijlemaker W. P. Antibody-dependent lymphocytotoxicity: an analysis of effector cell-target cell interactions Journal of immunology (Baltimore, Md. 1978;121 (2):499-504 [PubMed]
• van Oers M. H., Pinkster J., Zeijlemaker W. P. Quantification of antigen-reactive cells among human T lymphocytes European journal of immunology 1978;8 (7):477-484 [PubMed]

1977

• Zeijlemaker W. P., van Oers R. H., de Goede R. E., Schellekens P. T. Cytotoxic activity of human lymphocytes: quanitative analysis of T cell and K cell cytotoxicity, revealing enzyme-like kinetics Journal of immunology (Baltimore, Md. 1977;119 (4):1507-1514 [PubMed]
• Brutel de la Rivière A., Verhoef-Karssen P. R., van Oers M. H., Schoorl R., Feltkamp-Vroom T. M., von dem Borne A. E., Zeijlemaker W. P. Preparation and specificity testing of a rabbit anti-human thymocyte serum (with 1 colour plate) Vox sanguinis 1977;33 (5):257-265 [PubMed]
• van Oers M. H., Zeijlemaker W. P., Schellekens P. T. Separation and properties of EA-rosette-forming lymphocytes in humans European journal of immunology 1977;7 (3):143-150 [PubMed]
• van Oers M. H., Zeijlemaker W. P. The mixed lymphocyte reaction (MLR) stimulatory capacity of human lymphocyte subpopulations Cellular immunology 1977;31 (2):205-215 [PubMed]

1976

• Zeijlemaker W. P., van Oers M. H., Eijsvoogel V. P. Human lymphocyte subpopulations involved in MLC and CML Scandinavian journal of immunology 1976 (Suppl. 5):143-156 [PubMed]